Guojin Securities released a research report on April 26 stating that it gave Aier Ophthalmology (300015.SZ) a purchase rating. The main reasons for the rating include: 1) revenue shows strong resilience, and the number of outpatients and surgeries has increased steadily; 2) profitability has steadily increased due to the scale effect; 3) the country is steadily advancing the “1+8+N” strategy and strengthening strategic cooperation overseas. (Mainichi Keizai Shimbun)
国金证券4月26日发布研报称，给予爱尔眼科（300015.SZ）买入评级。评级理由主要包括：1）收入彰显强韧性，门诊量及手术量稳增；2）规模效应下盈利能力稳步提升；3）国内稳步推进“1+8+N”战略，海外加强战略合作。（每日经济新闻）
Guojin Securities released a research report on April 26 stating that it gave Aier Ophthalmology (300015.SZ) a purchase rating. The main reasons for the rating include: 1) revenue shows strong resilience, and the number of outpatients and surgeries has in
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.